Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Lecanemab moderately slows decline in early AD, associated with AEs
Lecanemab reduces brain amyloid burden and offers moderate slowing of cognitive decline in early Alzheimer’s disease (AD), but is associated with adverse events (AEs), according to the results of the phase III, double-blind, placebo-controlled CLARITY AD trial, presented at the 15th Clinical Trials on Alzheimer’s Disease (CTAD 2022) conference.
Lecanemab moderately slows decline in early AD, associated with AEs
06 Dec 2022
Stroke up 30 percent since 2001 in HK’s ≤55-year-olds
Researchers from the University of Hong Kong (HKU) report that the incidence of “young stroke” (ie, strokes occurring in those aged 18–55 years) has increased by 30 percent in Hong Kong’s residents since 2001.
Stroke up 30 percent since 2001 in HK’s ≤55-year-olds
05 Dec 2022
Dose reduction needed in HFrEF patients on sacubitril-valsartan
Some patients with heart failure with reduced ejection fraction (HFrEF) need a loop diuretic dose reduction within 2‒3 months following initiation of sacubitril-valsartan, suggests a study.
Dose reduction needed in HFrEF patients on sacubitril-valsartan
05 Dec 2022
Dip in serum cholesterol tied to higher pancreatic cancer risk
A recent decrease in total cholesterol levels may signal an aggravated risk of pancreatic cancer, reports a study. On the other hand, high serum cholesterol in the preceding years may exert a protective effect against pancreatic cancer.
Dip in serum cholesterol tied to higher pancreatic cancer risk
05 Dec 2022
Gut microbiome modulation reduces infections, shows other health benefits
A gut microbiota–derived synbiotic formula developed by researchers from the Chinese University of Hong Kong (CUHK) is shown in a randomized controlled trial to reduce the risk of bacterial and viral infections, including COVID-19, reduce the risk of adverse events (AEs) after COVID-19 vaccination, restore healthy gut microbiota, and provide other health benefits.